Min Li, PhD, Acting Biopharmaceutics Lead for the Division of Biopharmaceutics, discusses the scientific and risk-based framework associated with the Agency’s evaluation of invitro dissolution method development for generic immediate-release, extended-release and delayed-release solid oral drug products.
Learn more at: [ Ссылка ]
--------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming Training - [ Ссылка ]
SBIA Listserv - [ Ссылка ]
SBIA 2021 Playlist - [ Ссылка ]
SBIA LinkedIn: [ Ссылка ]
SBIA Training Resources - [ Ссылка ]
Twitter - [ Ссылка ]
Email - CDERSBIA@fda.hhs.gov
Phone - (301) 796-6707 I (866) 405-5367
